Commercializing Living Therapies with CCRM

Podcast details

Technical and general information from the podcast's RSS feed.

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://www.ccrm.ca/podcast/
24 shares

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

Publication history

Monthly episode publishing history over the past years.

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Convergence, collaboration and commercialization in cell and gene therapies

Season 4 · Episode 6

Thursday, May 15, 2025 • Duration 32:38

Featuring:

Molly Shoichet, PhD, O.C., O. Ont., FRS, University Professor and Pamela & Paul Austin Chair in Precision & Regenerative Medicine, University of Toronto

Audrey Greenberg, MBA, CEO & Founder, AG Capital Advisors

***

In this engaging episode of “Commercializing Living Therapies with CCRM,” we sit down with two leaders in the life sciences field: Molly Shoichet, a biomedical engineer and University Professor at the University of Toronto, and Audrey Greenberg, Founder and Managing Partner, AG Capital Advisors. Together, they bring a wealth of experience in commercializing scientific breakthroughs and building the infrastructure needed to bring transformative therapies to market.

Our guests explore some of the most exciting advances in cell and gene therapies today, including technologies with the potential to significantly impact patient outcomes. They also share insights into the companies they’re watching, the challenges and opportunities facing the field, and the evolving role of AI and automation in accelerating innovation. With practical advice on commercialization and reflections on public-private partnerships, this episode is a must-listen for anyone navigating the future of regenerative medicine.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Investing in the future of medicine: Trends, hurdles and opportunities in the CGT sector

Season 4 · Episode 5

Tuesday, April 15, 2025 • Duration 38:18

Reni Benjamin, Managing Director, Healthcare Equity Research at Citizens

Brock Reeve, CEO and Co-founder, Eos BioInnovation

***

In this episode of Commercializing Living Therapies with CCRM, host Krista Lamb speaks with Reni Benjamin and Brock Reeve about the current financial landscape for cell and gene therapies (CGTs). They explore the unique dynamics companies face, from securing funding to navigating regulatory hurdles, and discuss how investors assess risks and opportunities in the field. While recent headlines suggest industry struggles, our guests provide a deeper look at what these headlines really mean for the sector’s future.

The interview covers the promising developments that the field continues to see , including positive clinical trial results and major acquisitions that signal stronger investor interest. Reni and Brock discuss how pricing strategies, market access and reimbursement models shape the financial outlook for CGT companies. They also highlight key trends that could influence the industry’s next phase of growth. As the conversation unfolds, they share their perspectives on what excites them most about the future of regenerative medicine.

Whether you’re an investor, industry professional, or simply curious about the business side of CGT, this episode offers valuable insights into the evolving financial landscape of this innovative sector.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Navigating commercialization: Regional hubs, global solutions

Season 4 · Episode 4

Saturday, March 15, 2025 • Duration 23:09

Featuring:

Silvio Tiziani, CEO, CCRM Australia

Sarah Callens, CTO, CCRM Nordic

***

In this episode of Commercializing Living Therapies with CCRM, Silvio Tiziani, CEO, CCRM Australia, and Sarah Callens, CTO, CCRM Nordic, explore the opportunities and challenges of commercializing regenerative medicines, including cell and gene therapies, in their respective regions. While scientific discoveries abound, barriers such as regulatory hurdles, funding gaps and infrastructure limitations can slow the path to commercialization. Our guests provide insights into these obstacles and share what makes their regions well-positioned for success in this transformative field.

In addition, we hear how global collaboration can accelerate the development and commercialization of these therapies. Silvio and Sarah highlight the strengths of the CCRM model and its potential to guide other regions looking to build thriving regenerative medicine (RM) ecosystems. As they look to the future, they share their goals, their excitement about the industry’s evolution, and the key factors that will shape the next generation of RM innovations.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Enabling patient access to cell and gene therapies

Season 4 · Episode 3

Saturday, February 15, 2025 • Duration 28:20

Featuring:

Durhane Wong-Rieger, PhD, President and CEO, Canadian Organization for Rare Disorders

Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult

***

In this episode, we dive into the critical topic of enabling patient access to cell and gene therapies with two leaders in the field. Jacqueline Barry, an expert in the development and adoption of advanced therapies, shares her insights on the challenges involved with bringing innovative treatments to patients, from regulatory hurdles to affordability concerns. Durhane Wong-Rieger, an advocate for people living with rare diseases, discusses the unique barriers faced by patients with these conditions and the limited treatment options available for many rare disorders.

Together, our guests explore potential solutions to improve access to care, highlighting the importance of collaboration between industry, stakeholders, governments and healthcare providers. They address the pressing issue of cost and discuss how industry is working to make these transformative treatments more affordable and more widely available. The conversation also touches on efforts to expand access beyond North America and the U.K., where the need for advanced therapies is significant but often unmet.

As the field of regenerative medicine continues to evolve, Drs. Barry and Wong-Rieger reflect on the developments that inspire optimism for the future. From innovative technologies to new models of partnership, they share their thoughts on future progress and the changes they believe will make a lasting impact on patient care.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Unapproved stem cell therapies: Risks, realities and responsibilities

Season 4 · Episode 2

Wednesday, January 15, 2025 • Duration 35:30

Featuring:

Paul Knoepfler, PhD, Professor of Cell Biology and Human Anatomy, UC Davis School of Medicine

Amy Zarzeczny, PhD LLM, Associate Professor, Johnson Shoyama Graduate School of Public Policy, University of Regina

***

Unapproved stem cell therapies continue to be a significant concern in the regenerative medicine field. In this episode, Drs. Paul Knoepfler and Amy Zarzeczny discuss the issue. Listeners will hear the risks and implications of these treatments, and why they are not just a problem abroad but also in North America. Our guests discuss the medical dangers of these therapies, and the potential for them to erode public trust in science.

Desperation often drives patients to seek unapproved treatments. Drs. Knoepfler and Zarzeczny explore how professionals in the field can better communicate safety concerns without alienating patients and they highlight the role of regulation in addressing this issue. The experts also share what companies and governments can do to help educate the public.

This insightful conversation sheds light on the challenges and opportunities for improving patient safety and addressing this growing issue.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Biomanufacturing redefined: The role of AI and robotics in producing cell and gene therapies

Season 4 · Episode 1

Sunday, December 15, 2024 • Duration 34:59

Featuring:

Christopher P. Boone, PhD, Group Vice President, Research Services, Health & Life Sciences, Oracle

Kenneth L. Harris, Chief Strategy Officer and Head of AI, OmniaBio Inc.

***

We are excited to share the first episode in the fourth season (!) of Commercializing Living Therapies with CCRM. A big thanks to all our listeners.

In this episode, we explore how artificial intelligence (AI) and robotics are shaping the biomanufacturing facility of the future. Our guests discuss the technologies behind automation, including robotics, AI and machine learning, and how they play a role in development and manufacturing facilities for cell and gene therapies. They also cover the impact of these technologies on resolving challenges, like production bottlenecks, cost management and consistent quality control. As well, they illuminate how these technologies can affect both patients and clinicians.

The episode concludes by highlighting some key considerations, including the importance of implementing change management activities as biomanufacturers bring both their organizations and customers along as their facilities evolve, as well as the need to upskill and reskill talent, and to collaborate with experts, to support scalability.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Expert insights for taking a cell or gene therapy company from vision to reality

Season 3 · Episode 6

Monday, April 15, 2024 • Duration 26:25

Featuring:

Jacki Jenuth, PhD, Partner and COO, Lumira Ventures

Robin Quirk, PhD MBA, Vice President, Technology Sourcing and Venture Development, CCRM

***

In this episode, we explore the dynamics of venture capital (VC) and company creation with Jacki Jenuth, Partner and COO, Lumira Ventures, and Robin Quirk, Vice President, Technology Sourcing and Venture Development, CCRM. The conversation covers the essence of venture capital funding, from how VCs evaluate investment potential to crucial considerations for founders who are attracting investment during product development.

We also discuss red flags and common pitfalls for founders seeking funding along with the current enthusiasm among VCs for investing in cell and gene therapies. Our guests explain the strategy of bundling technologies to create stronger companies.

The episode concludes with a glimpse into exciting projects and investments in the cell and gene therapy space, highlighting the ongoing innovation and opportunities in this field.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Regulators' strategies for managing the surge in cell and gene therapies

Season 3 · Episode 5

Thursday, February 15, 2024 • Duration 27:35

Featuring:

Michael Rosu-Myles, PhD, Executive Director, Health Canada

Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine

***

Currently, there are more than 2,000 cell and gene therapies in clinical trials worldwide. With a goal of ensuring that safe and quality products are approved for use by patients, regulators determine whether these innovative therapies move from the lab to market.

In this interview, Michael Rosu-Myles, PhD, Executive Director, Health Canada, and Josephine Lembong, PhD, Senior Manager, Science and Industry Affairs, Alliance for Regenerative Medicine, provide listeners with an exclusive look at how regulators are preparing for an increased number of applications for cell and gene therapy products in the years to come.

Our guests discuss how Health Canada, the U.S. Food and Drug Administration and European Medicines Agency have created new regulatory frameworks and offices to enhance their ability to review cell and gene therapy submissions. Listeners will learn how companies that are planning a submission can prepare to work successfully with regulators, whether regulators consider the potential price tags of these therapies, and how patients benefit from regulators’ work.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

How Creative Destruction Lab accelerates the advanced therapies industry

Season 3 · Episode 4

Monday, January 15, 2024 • Duration 24:23

Featuring:

Sonia Sennik, Executive Director, Creative Destruction Lab

Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM

***

In many science-oriented fields, including regenerative medicine and advanced therapies, researchers and company founders often require additional support and expertise to successfully commercialize their discoveries.

With a mission of enhancing the commercialization of science for the betterment of humankind, Creative Destruction Lab is a valuable resource for start-up founders to help de-risk their business and maximize their probability of success. Its Advanced Therapies stream supports founders solving biological, medical and healthcare problems using innovative applications of cell and gene therapies, and other biological products.

In this interview, Sonia Sennik, Executive Director, Creative Destruction Lab, and Glenn MacLean, Director, Technology Sourcing and Venture Development, CCRM, discuss how Creative Destruction Lab’s processes and mentors can help drive a discovery to the market. Our guests explain the practical steps and tactics, and also discuss the program’s potential future impact on Canada’s regenerative medicine and advanced therapies sector.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

The synergy solution: How public-private partnerships advance regenerative medicine

Season 3 · Episode 3

Friday, December 15, 2023 • Duration 34:43

Featuring:

Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult

Michael May, PhD, President and Chief Executive Officer, CCRM

***

Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the commercialization pathway. Our guests share highlights from their organizations, including the types of partners they have worked with, and the infrastructure and facilities they have helped to create.

The interview concludes with a discussion of how public-private partnerships will benefit patients in the future by improving the factors that lead to market access and adoption, such as developing markets, promoting acceptability, reducing the cost of goods, and enabling the supply chain.

Thanks for listening to Commercializing Living Therapies with CCRM. Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service. Find more episodes at ccrm.ca/podcast.

Read moreCollapse

Commercializing Living Therapies with CCRM – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Commercializing Living Therapies with CCRM – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Other1

Apple Podcasts

Spotify